| 前收市價 | 0.2500 |
| 開市 | 0.3000 |
| 買盤 | 0.4500 |
| 賣出價 | 0.5500 |
| 拍板 | 45.00 |
| 到期日 | 2024-06-07 |
| 今日波幅 | 0.2500 - 0.3000 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 517 |
Yahoo財經美股日誌｜納指首破萬七點 英偉達爆上7%
美股在假期後先升後回，受惠英偉達上達1,100美元帶動，納斯達克指數曾歷史性突破17,000點以上，午市一度近抹去所有升幅，惟最終能守穩在心理關口收市；道瓊斯指數曾跌近300點，標普500指數則近平收。債市向下，美國國債拍賣需求弱，10年期國債息率升7點子以上。中東局勢升溫，紐約期油升2.7%。
BenzingaZantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit
A Chicago jury rejected an Illinois woman’s claim that the discontinued heartburn drug Zantac caused her colon cancer. This case is the first of thousands of similar lawsuits. The jury in Cook County, Illinois, found that Angela Valadez, an 89-year-old Illinois resident, did not prove her cancer was linked to her Zantac use. Related: GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims. Valadez alleged that her cancer resulted from taking over-the-
BenzingaGSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims
GSK Plc (NYSE:GSK) has been reportedly sued by an independent Connecticut laboratory, Valisure, accusing the pharmaceutical giant of defrauding the U.S. government and taxpayers by concealing cancer risks associated with Zantac, once a blockbuster heartburn drug. Related: Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac. In a whistleblower complaint filed on Monday, Valisure claimed GSK violated the federal False Claims Act by hid
